Merck KGaA, Darmstadt, Germany Awards €1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation (GFI)
- Two projects are awarded funds to advance the fertility field
- Professor Lunenfeld honored with Merck KGaA, Darmstadt, Germany Lifetime Achievement Award
- The company is committed to driving innovation through evolving the product portfolio and investing in potential breakthrough research
Darmstadt, Germany, July 5, 2017 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck KGaA, Darmstadt, Germany Grants for Innovation in 2009, Merck KGaA, Darmstadt, Germany’s GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area. This year, the GFI Award Ceremony included the announcement of the Merck KGaA, Darmstadt, Germany Lifetime Achievement Award in Fertility Innovation.
To recognize Merck KGaA, Darmstadt, Germany’s belief in progress through innovation, the GFI awardees were revealed in a ceremony at the European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Geneva, Switzerland. The winning projects truly reflect the global nature of the program, ranging from research in Italy to Brazil.
Professor Bruno Lunenfeld, a speaker at the GFI 2017 ceremony, was honored with the Merck KGaA, Darmstadt, Germany Lifetime Achievement Award for his revolutionary work within the fertility field since 1954. At the ceremony he provided an overview on the discovery of human gonadotropins from postmenopausal urine.
“Professor Lunenfeld’s pioneering achievements in the field of fertility are a huge inspiration to us at Merck KGaA, Darmstadt, Germany. It is highly motivating to consider the breadth of his contributions. For more than 60 years now, his expertise and experience have greatly contributed to our efforts to improve the quality of patient care,” said Belén Garijo, member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO Healthcare, when presenting Professor Lunenfeld with the Merck KGaA, Darmstadt, Germany Lifetime Achievement Award.
The research investments through the GFI is core to the innovation strategy of the biopharma business of Merck KGaA, Darmstadt, Germany, and in the quest for increased success rates within fertility treatment. In this year’s GFI, two winning projects were selected from 46 global proposals with the common goal of advancing the fertility field. The GFI was launched in 2009, and is dedicated to transforming innovative translational fertility research projects into actual solutions with the aim to improve fertility treatment outcomes. Merck KGaA, Darmstadt, Germany proudly announced the 2017 GFI awardees during the ceremony:
- Endometrial Notch pathway as a novel target for improving implantation efficiency; Luisa Campagnolo, PhD
- Pharmacogenetic algorithm for individualized controlled ovarian stimulation (iCOS) in assisted reproductive technology cycles; Caio Parente Barbosa, MD, PhD, MS and Matheus Roque, MD
About the Grant for Fertility Innovation (GFI)
Merck KGaA, Darmstadt, Germany announced the initiation of the GFI program in 2009 to support the advancement of science and innovative technologies in the fertility field. This grant is awarded every year to translational research projects that can potentially improve baby birth rate for the benefit of the patients. Each project is blinded and evaluated by a jury of experts according to five criteria: support to increase baby birth rate; innovative research; scientific rationale; feasibility and practical utility.
For further information about the GFI and how to apply for next year’s grants, please visit: www.grantforfertilityinnovation.com
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
MilliporeSigma today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program.